Pengcheng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pengcheng Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Changtao Jiang
Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China
1 shared publication - Chenghao Guo
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China
1 shared publication - En-Qiang Chen
Center of Infectious Diseases, West China Hospital of Sichuan University
1 shared publication - Hai‐Yang Yuan
MAFLD Research Center, Department of Hepatology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
1 shared publication - Jie Qiao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
1 shared publication - Jinjun Chen
Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- Top Cited Papers
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eadp5540
A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite–CerS6–ceramide axis
The gut microbiota is known to be associated with a variety of human metabolic diseases, including metabolic dysfunction–associated steatohepatitis (MASH). Fungi are increasingly recognized as important members of this community; however, the role of fungal symbionts in metabolic diseases is unknown. We have systematically isolated and characterized gut fungi, identifying Fusarium foetens as an intestinal symbiotic filamentous fungus in mice. F. foetens reverses MASH progression in mouse models through an intestinal ceramide synthetase 6 (CerS6)–ceramide axis. Moreover, we identified FF-C1, a secondary metabolite from F. foetens , as a CerS6 inhibitor that has an endogenous protective effect on MASH progression.
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eadp5540
Top Cited PapersA symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite–CerS6–ceramide axis
The gut microbiota is known to be associated with a variety of human metabolic diseases, including metabolic dysfunction–associated steatohepatitis (MASH). Fungi are increasingly recognized as important members of this community; however, the role of fungal symbionts in metabolic diseases is unknown. We have systematically isolated and characterized gut fungi, identifying Fusarium foetens as an intestinal symbiotic filamentous fungus in mice. F. foetens reverses MASH progression in mouse models through an intestinal ceramide synthetase 6 (CerS6)–ceramide axis. Moreover, we identified FF-C1, a secondary metabolite from F. foetens , as a CerS6 inhibitor that has an endogenous protective effect on MASH progression.